"
Team:Carnegie Mellon/Project/Abstract
From 2013.igem.org
Enpederson (Talk | contribs) |
Enpederson (Talk | contribs) |
||
| Line 1: | Line 1: | ||
{{:Team:Carnegie_Mellon/Templates/header}} | {{:Team:Carnegie_Mellon/Templates/header}} | ||
<html> | <html> | ||
| + | <br> | ||
<br> | <br> | ||
<br> | <br> | ||
| Line 9: | Line 10: | ||
<h2>Impact</h2> | <h2>Impact</h2> | ||
<p> | <p> | ||
| - | + | On September 16, 2013 the CDC released to the public <a href="http://www.cdc.gov/drugresistance/threat-report-2013/index.html">“Antibiotic Resistance Threats in the United States, 2013”</a>. This document is intended to raise public awareness of the problems associated with overuse and misuse of antibiotics and to outline the threats to society caused by these organisms. The organisms have been categorized by hazard level as urgent, serious and concerning. Over 2 million illnesses and 23,000 deaths per year are a direct result of antibiotic resistance. The CDC reports 4 major steps to tackle the problem including: | |
<ol> | <ol> | ||
<li>Preventing Infections, Preventing the Spread of Resistance</li> | <li>Preventing Infections, Preventing the Spread of Resistance</li> | ||
| Line 17: | Line 18: | ||
</ol> | </ol> | ||
<br> | <br> | ||
| - | + | <h2>Summary</h2> | |
| + | <p> | ||
| + | There is a great need for new antimicrobial strategies. Phage therapy represents a completely different solution. Incorporating KillerRed phototoxicity provides another level of controlled killing. Phages are biological entities, which, theoretically, can be engineered to evolve at rates comparable of the natural evolution of bacteria if they happen to develop resistances to infection. Many phages are temperate, meaning that they can enter the lysogenic phase, which is undesirable for a killing phage. The addition of KillerRed to the system offers a second method of killing in the lysogenic phage. Thus, our system explores the possibility that temperate phages can also be used for phage therapy and bacteria killing applications. Our project establishes a first step in the production of phage therapies that | ||
| + | </p> | ||
| + | |||
| + | <h2>Background</h2> | ||
| + | <br> | ||
| + | <b>Discovery of Antibiotics</b> | ||
| + | <br><p> | ||
| + | Arsphenamine is an arsenic compound that was discovered in 1909, to have antisyphilitic properties by Sahachiro Hata and Paul Ehrlich. In 1929, Sir Alexander Fleming published the results of his study of a substance that he named penicillin. This compound was released by Penicillium fungi and killed bacteria. These antibiotics function by inhibiting an enzyme involved in crosslinking of the peptidoglycan cell wall of gram-positive bacteria. Resistance to the beta lactam antibiotics is derived from beta-lactamase, an enzyme that cleaves the drug and inactivates it. The gene for this enzyme is commonly used as a selectable marker in recombinant DNA laboratories to confer resistance to ampicillin. Today there are antibiotics of the cephalosporin family that are derived from the compound isolated in 1945 by Giuseppe Brotzu, from the fungus Cephalosporium acremonium.</p> | ||
| + | |||
| + | |||
<br><table border="1"> | <br><table border="1"> | ||
<tr><td> | <tr><td> | ||
Revision as of 16:32, 26 September 2013
Abstract
Due to the widespread misuse and overuse of antibiotics, drug resistant bacteria now pose significant risks to health, agriculture and the environment. An alternative to conventional antibiotics is phage therapy. However, many temperate phage also form prophage. Our approach to antibiotic resistance is to engineer a temperate phage, Lambda, with light-activated production of superoxide. The fluorescent protein KillerRed was cloned into a plasmid vector and lambda gt11 with the IPTG inducible lac promoter. Lysogens were isolated and these strains were characterized and compared to E. coli with KillerRed from high-copy plasmids. Light activation of KillerRed resulted in decreased cell numbers. In addition, we modeled our system at multiple scales, including populations of phage and bacteria, KillerRed gene expression, ROS production, and effects of light. Having two methods of killing, lysis and superoxide, decreases the probability of developing resistance and our system overcomes the prior limitations of using wild-type temperate phages.
Impact
On September 16, 2013 the CDC released to the public “Antibiotic Resistance Threats in the United States, 2013”. This document is intended to raise public awareness of the problems associated with overuse and misuse of antibiotics and to outline the threats to society caused by these organisms. The organisms have been categorized by hazard level as urgent, serious and concerning. Over 2 million illnesses and 23,000 deaths per year are a direct result of antibiotic resistance. The CDC reports 4 major steps to tackle the problem including:
- Preventing Infections, Preventing the Spread of Resistance
- Tracking
- Improving Antibiotic Prescribing/Stewardship
- Developing New Drugs and Diagnostic Tests
Summary
There is a great need for new antimicrobial strategies. Phage therapy represents a completely different solution. Incorporating KillerRed phototoxicity provides another level of controlled killing. Phages are biological entities, which, theoretically, can be engineered to evolve at rates comparable of the natural evolution of bacteria if they happen to develop resistances to infection. Many phages are temperate, meaning that they can enter the lysogenic phase, which is undesirable for a killing phage. The addition of KillerRed to the system offers a second method of killing in the lysogenic phage. Thus, our system explores the possibility that temperate phages can also be used for phage therapy and bacteria killing applications. Our project establishes a first step in the production of phage therapies that
Background
Discovery of Antibiotics
Arsphenamine is an arsenic compound that was discovered in 1909, to have antisyphilitic properties by Sahachiro Hata and Paul Ehrlich. In 1929, Sir Alexander Fleming published the results of his study of a substance that he named penicillin. This compound was released by Penicillium fungi and killed bacteria. These antibiotics function by inhibiting an enzyme involved in crosslinking of the peptidoglycan cell wall of gram-positive bacteria. Resistance to the beta lactam antibiotics is derived from beta-lactamase, an enzyme that cleaves the drug and inactivates it. The gene for this enzyme is commonly used as a selectable marker in recombinant DNA laboratories to confer resistance to ampicillin. Today there are antibiotics of the cephalosporin family that are derived from the compound isolated in 1945 by Giuseppe Brotzu, from the fungus Cephalosporium acremonium.
 Figure 1:Antibiotic resistance timeline since 1940 |
 Figure 2: Antibiotic development pipeline since 1980 |
References
Antibiotic resistance threats in the United States, 2013. The Center for Disease Control. 9/16/2013.
